# Rhythm expects to dose first Phase III bivamelagon HO patients in January as it commits to $350M royalty buy-down

- Source: Seeking Alpha Market Currents
- Published: 2026-11-03T19:57:14+00:00
- Category: Markets
- Original: https://seekingalpha.com/news/4663973-rhythm-expects-to-dose-first-phase-iii-bivamelagon-ho-patients-in-january-as-it-commits-to?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news
- Canonical: https://groundlevelnews.com/story/rhythm-expects-to-dose-first-phase-iii-bivamelagon-ho-patients-in-janu-258dd0/

Read the full report from the original publisher.

_Ground Level News shows a short summary only; the full article and all rights belong to Seeking Alpha Market Currents._